Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Integra Lifesciences (IART)

Integra LifeSciences Q2 revenue rises 0.8% to $418.8 million; adjusted EPS $0.56

Mixed Impact 4 of 5 earnings Written later

Integra LifeSciences reported second-quarter 2026 revenue of $418.8 million, up 0.8% on a reported basis, and adjusted earnings of $0.56 per diluted share, up from $0.45. It cut its reported full-year 2026 revenue range to $1.654 billion to $1.695 billion, citing a stronger U.S. dollar, while reaffirming its organic growth and adjusted EPS guidance.

Key points

  • Q2 2026 GAAP EPS was $0.06, compared with a $(6.31) loss in Q2 2025, which included a $511.4 million goodwill impairment charge
  • Adjusted EBITDA was $78.4 million, or 18.7% of revenue, versus $71.2 million, or 17.1%, a year earlier
  • Full-year reported revenue guidance was lowered from $1.662 billion-$1.702 billion to $1.654 billion-$1.695 billion; 2026 adjusted EPS guidance of $2.40-$2.50 was reaffirmed
  • Q3 2026 guidance calls for reported revenue of $410 million to $425 million and adjusted EPS of $0.53 to $0.61

The filing

CompanyIntegra Lifesciences (IART)
Form8-K, current report
Filed with the SECJul 29, 2026, 6:15 AM ET
Accession number0000917520-26-000055

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.